Get the latest news, insights, and market updates on AMPH (Amphastar Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative?
In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability... Dec 16, 2025 - $AMPH
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 14.6% over the past six months, topping the S&P 500 by 1.5 percentage points. Dec 16, 2025 - $AMPH
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide ... Dec 15, 2025 - $AMPH
2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses. Dec 12, 2025 - $AMPH
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models. Dec 9, 2025 - $AMPH
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.7% in the afternoon session after positive analyst sentiment and technical trading indicators pointed to potential upside for the stock. The cautiously optimistic view from analysts included three buy ratings and three hold ratings, with no sell recommendations. The average price target was set at $32.00, reflecting a potential upside. Adding to the positive tone, insider sentiment was reported as positive, based on Dec 3, 2025 - $AMPH
Amphastar Pharmaceuticals (AMPH) Jumps 6.5% After Q3 Beat and Conference Reveal—Has the Investment Case Shifted?
Amphastar Pharmaceuticals reported third-quarter 2025 earnings ahead of analyst expectations, with net revenues of US$191.8 million and non-GAAP adjusted net income of US$44.6 million, while announcing executive participation in the 37th Annual Piper Sandler Healthcare Conference in early December. An important development is the company’s ability to use major industry events to discuss its robust product pipeline and regulatory progress directly with investors and analysts. We’ll review how... Nov 29, 2025 - $AMPH
A Look at Amphastar Pharmaceuticals (AMPH) Valuation Following Strong Quarterly Results and Pipeline Progress
Amphastar Pharmaceuticals (AMPH) just posted quarterly results that came in ahead of Wall Street estimates, drawing attention to both revenue growth and solid earnings. The company’s ongoing expansion efforts and active drug development also add to the story for investors. See our latest analysis for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals has seen a stretch of volatility this year, with recent upbeat earnings and a new regulatory focus boosting sentiment. While the 1-month share... Nov 29, 2025 - $AMPH
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple